Noxafil (posaconazole) / Merck (MSD), Ligand  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Noxafil (posaconazole) / Merck (MSD)
2018-000972-14: Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole alone in non- or mildly- immunocompromised patients with Chronic Pulmonary Aspergillosis: a prospective, randomized, single blind study, (single aspergilloma excluded).

Not yet recruiting
3
224
Europe
Ambisome®, Sporanox®, Vfend®, NOXAFIL, Powder for solution for infusion, Capsule, Tablet, Ambisome®, Sporanox®, Vfend®, NOXAFIL
CHU DE POITIERS, DGOS, JASSEN, MSD-MERCK, PFIZER, ELIVIE, SOS-Oxygen, VIVISOL, ORHE PHARMA
Chronic Pulmonary Aspergillosis, Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]
 
 
ReSPECT, NCT04368559 / 2017-004981-85: Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Recruiting
3
600
Europe, Canada, US, RoW
Rezafungin for Injection, Intravenous antifungal therapy, Posaconazole, Noxafil, Fluconazole, Generic Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Bactrim, Septra, Intravenous Placebo, Placebo Infusion, Oral Placebo, encapsulated cellulose
Mundipharma Research Limited
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
12/25
12/25
2019-004511-31: Prospective validation and clinical evaluation of a new posaconazole dosingregimen for children and adolescents with cystic fibrosis and Aspergillus infection.

Ongoing
2/3
135
Europe
Noxafil - oral suspension 40 mg/ml, Noxafil 100 mg, [NA], [na], Oral suspension, Gastro-resistant tablet, Noxafil - oral suspension 40 mg/ml, Noxafil 100 mg
Bambino Gesù Children's Hospital, IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA, Innovative Medicines Initiative 2, European Union’s Horizon 2020
Cystic Fibrosis and Aspergillus Infection, Aspergillus infection in people with cystic fibrosis, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 

Download Options